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Abstract 
 
The histological subtyping and the grading of gliomas in the World Health 
Organization classification of brain tumors was originally designed mainly to provide 
clinicians with guidance as to the natural course of disease and the necessity of 
further treatment beyond surgery. The profound prognostic impact of this pathological 
grading has been confirmed over the last decades in numerous retrospective 
analyses. Yet, it has also become clear that tumors virtually identical by morphology 
may have very different outcomes and that molecular markers may aid in deriving 
more detailed prognostic information. The 1p/19q codeletion in oligodendroglial 
tumors became paradigmatic in this regard: patients with 1p/19q-deleted tumors 
derive much more benefit from radiotherapy or chemotherapy than patients with 
tumors lacking this aberration. Thus, the 1p/19q status does not help to select among 
different genotoxic treatments. The first molecular marker attributed a predictive 
power specifically for benefit from alkylating agent chemotherapy was promoter 
methylation of the O6-methylguanylmethyltransferase gene. However, it now seems 
that this predictive effect may be limited to glioblastoma and that implementation of 
the according test in clinical practice is a major challenge. The identification of 
isocitrate dehydrogenase mutations as typical changes restricted to certain types of 
gliomas and the rapid development of common mutation-specific antibodies has 
provided a major advance in subclassifying gliomas, but not resulted in novel 
treatment strategies yet. A specific type of epidermal growth factor receptor mutation, 
EGFRvIII, has emerged as a target for vaccination. Ongoing high-throughput 
analyses are likely to yield novel candidate biomarkers in due course, suggesting that 
molecular neuropathology will have an increasing impact in clinical neurooncology 
very soon. 
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Introduction 
 
The current World Health Organization Classification of Tumors of the Nervous 
System allows for a histomorphological subtyping of brain tumors and a grading into 
WHO grades I to IV according to the expected degree of malignancy (1). One major 
goal of the WHO classification was to provide clinicians with guidance as to the 
natural course of disease and the indication to withhold or offer further treatment 
beyond surgery, specifically radiotherapy or chemotherapy. The profound prognostic 
impact of the pathological grading afforded by the WHO classification has been 
confirmed over the last decades in numerous retrospective analyses. Yet, these 
studies as well as prospective intervential trials have also shown that tumors identical 
by morphological criteria may have highly different outcomes and that molecular 
markers may aid in deriving more detailed prognostic information up-front. Numerous 
such molecular markers in the field of glioma have been explored, many without 
attracting enduring attention. Some, however, continue to raise interest over years, 
such as p53 mutations, epidermal growth factor receptor (EGFR) mutations, and the 
1p/19q codeletion, others such as O6-methylguanylmethyltransferase (MGMT) 
promoter methylation and mutations of isocitrate dehydrogenase (IDH) 1 and B-Raf, 
are subject of ongoing studies and controversies (Table, Figure). Moreover, powerful 
high-throughput analyses, which also let to the identification of IDH as a mutational 
target (2), are likely to yield novel diagnostic and prognostic information in the very 
near future. The present article summarizes and extends previous reviews on the 
development of molecular markers for the differential diagnosis and stratified 
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management of gliomas (3-7). The potential value of molecular markers includes, but 
is not limited: 
 to aid in the differential diagnosis of brain tumors that are at times difficult to 
distinguish 
 to allow prognostication within tumor entities 
 to allow prediction of response or lack of response to a specific type of 
treatment 
Notably the distinction between prognostic and predictive molecular factors is not 
consistently made in the literature and has given rise to controversies and 
misconceptions, e.g., the false assumption that patients with 1p/19q-codeleted 
oligodendrogliomas should be treated with chemotherapy or chemotherapy plus 
radiotherapy rather than radiotherapy alone (see below). 
 
 
P53 
 
The tumor suppressor protein (TP) 53 acts mainly as a transcription factor that 
controls the transcription of several genes involved in cell cycle arrest, DNA repair, 
senescence and apoptosis, e.g., p21 or bax. Mutations of the p53 gene or effectors 
of the p53 pathway are among the most common molecular aberrations in human 
cancers. Among gliomas, p53 mutations are relatively common in WHO grade II and 
III tumors and accordingly also in secondary glioblastomas, that is, glioblastomas 
progressing from previously lower grade gliomas. In contrast, p53 mutations are 
relatively rare in glioblastoma. 
Since p53 controls DNA damage response pathways and is thought to promote 
either DNA repair and survival, or irreversible growth arrest, traditional views held 
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that the p53 status should correlate with responses to radiotherapy or DNA damaging 
agent chemotherapy. While this can be nicely modelled in cell culture models and 
p53 knockout mice, such an association could never be demonstrated in large 
prospective clinical trials, neither in gliomas nor in other tumors. In contemporary 
studies from the German Glioma Network, the p53 status was not associated with 
progression-free survival in patients with WHO grade II gliomas managed with 
surgery alone (8) and not with progression-free or overall survival of glioblastoma 
patients treated with radiotherapy plus concomitant and adjuvant temozolomide (9). 
Possibly further molecular changes resulting from the loss of the p53 checkpoint 
control make tumors too heterogeneous to allow prediction of their behaviour in 
response to genotoxic stress. Moreover, the p53 pathway can be disabled at multiple 
levels other than p53 itself, accordingly, p53 signalling alterations may be present in 
87% of all glioblastoma patients whereas the p53 mutation rate is only 15-30% (10). 
Accordingly, there is at present no need to know the p53 status for any clinical 
decision making in the glioma field. There are at least two scenarios where this may 
change, first, mutant p53 proteins exhibiting immunogenic epitopes could be 
explored as targets for immunotherapy, second, p53 mimetic drugs which induce 
conformational changes and thereby transcriptional activation of mutant p53 variants 
could be assessed in subgroups of glioma patients carrying appropriate mutations. 
 
 
EGFR 
 
Amplification, constitutive activation or increased expression of the epidermal growth 
factor receptor (EGFR) gene may promote EGFR signalling and thereby proliferation, 
invasiveness and resistance to cell death induction. EGFR amplification or mutational 
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activation are rare in gliomas of lower WHO grades, but frequent in primary 
glioblastomas and glioblastoma in elderly patients (9,10). EGFR overexpression has 
been associated with inferior prognosis in some, but not all studies, and a major 
prognostic impact in glioblastoma can be ruled out. Numerous EGFR-targeted agents 
including tyrosine kinase inhibitors such as gefitinib or erlotinib as well as antibodies 
have been explored in patients with newly diagnosed or recurrent glioblastoma, but 
never produced a signal for activity justifying phase III development. It has been 
argued that upfront EGFR status determination to enrich patients likely to respond to 
EGFR-targeted treatments might be necessary to improve the outcome of anti-EGFR 
trials in glioblastoma. Thus it has been proposed that patients with high EGFR 
expression and low levels of phosphorylated protein kinase B/Akt respond better to 
erlotinib than those with low levels of EGFR expression and high levels of 
phosphorylated protein kinase B/Akt (11). Further, it was reported that the 
coexpression of EGFRvIII and phosphatase-and-tensin-homolog-on-chromosome-
ten (PTEN) by glioblastoma cells was associated with responsiveness to EGFR 
kinase inhibitors (12). However, neither of these observations was confirmed in the 
prospective randomized EORTC 26034 trial on erlotinib in recurrent glioblastoma 
(13). Since the EGFR status is not strongly prognostic and since no EGFR-targeting 
agents are approved for glioma treatment, there is currently no need for the 
determination of EGFR mutation or expression status outside a clinical trial, and its 
knowledge will not influence clinical decision making. However, a specific type of 
EGFR mutation, EGFRvIII, which gives rise to a truncated receptor that is active 
independent of ligand, produces a neoantigen that might be amenable to 
immunological targeting (14,15). Thus the detection of EGFRvIII might assume 
relevance at least for inclusion into clinical trials in the next few years. 
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1p/19q 
 
Combined losses of genetic material from chromosomal arms 1p and 19q, now 
commonly referred to as 1p/19q co-deletions, result from an unbalanced 
translocation which leads to the loss of one hybrid chromosome and thereby loss of 
heterozygosity (LOH) (16). These observations early on indicated the presence of 
tumor suppressor genes on 1p or 19q. 1p/19q co-deletions are almost never found in 
non-glial tumors and are strongly associated with oligodendroglial morphology. In 
WHO grade II gliomas, the absence or presence of this biomarker does not correlate 
with progression-free survival in patients treated by surgery alone, but neither with 
radiotherapy nor chemotherapy (8,17). However, they identify anaplastic glioma 
patients with a superior outcome independent of whether these patients are treated 
with radiotherapy or chemotherapy or both (18-20). In glioblastoma, 1p/19q 
codeletions are rare and of unknown biological significance. The higher effectivity of 
radiotherapy and chemotherapy in oligodendroglioma patients with 1p/19q 
codeletions has given rise to the hypothesis that these chromosomal regions harbour 
not only tumor suppressor genes, but also important genes which may determine 
cellular sensitivity to genotoxic stress or cell death stimuli in general. However, only 
very recently have the first convincing candidate genes been identified. By means of 
coding exon sequencing, mutations in two genes hitherto not related to gliomas, the 
CIC gene, a homolog of the Drosophila gene capicua) on chromosome 19q, and the 
FUBP1 gene, which encodes the “far upstream element (FUSE) binding protein” on 
chromosome 1p, were found in a relevant proportion of oligodendroglial tumors (21). 
To what extent mutations in CIC or FUBP1 contribute to oligodendrogliomagenesis or 
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the radiochemosensitivity of 1p/19q-codeleted oligodendrogliomas is currently under 
intense investigation. 
 
 
MGMT 
 
MGMT is a DNA repair enzyme that reverses the alkylation of DNA induced by 
alkylating agent chemotherapy, including nitrosoureas and temozolomide. The 
MGMT protein is consumed during this process by its targeting to the proteasome 
and is therefore often classified as a suicide enzyme. An association of MGMT 
expression and the efficacy of alkylating agent chemotherapy in glioblastoma has 
been proposed for more than 20 years (4). However, most studies reporting a 
prognostic impact of MGMT in glioblastoma examined promoter methylation of the 
MGMT promoter rather than protein levels or activity in the tumor cells. In fact, there 
was generally poor correlation between promoter methylation and loss of protein and 
promoter methylation correlated better with outcome than MGMT protein 
determination by immunochemistry (4,22). The reasons for these discrepancies may 
have included poor quality antibodies or difficulties in distinguishing MGMT-
expressing tumor from non-tumor host infiltrating cells. Alternatively, MGMT promoter 
methylation may not always result in loss of protein expression and may signify a 
biological feature with significance beyond MGMT, that is, there may be a pattern of 
gene silencing by methylation that predicts a better outcome (23). The MGMT 
promoter methylation status shows little intratumoral heterogeneity (24) and is 
preserved at recurrence in most glioblastomas (25,26). 
In the context of the pivotal trial that showed the superiority of concomitant and 
adjuvant temozolomide plus radiotherapy over radiotherapy alone (27), MGMT 
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promoter methylation was strongly associated with the extent of benefit from the 
addition of chemotherapy in the experimental arm (28), but had only minor prognostic 
impact for progression-free survival in patients treated with radiotherapy alone. This 
set of data is currently the only to demonstrate that MGMT promoter methylation is 
not only an overall prognostic factor, but predictive of benefit from chemotherapy, if 
only in glioblastoma. The strong prognostic role of MGMT promoter methylation has 
recently been confirmed in the RTOG 0525/ EORTC/NCCTG Intergroup Study that 
investigated three weeks on one week off adjuvant temozolomide dose intensification 
in comparison with the standard EORTC/NCIC treatment schedule. While there was 
no difference in progression-free or overall survival, the primary endpoint, between 
both treatment arms, overall survival was 23.2 months in patients with MGMT 
promoter-methylated tumors as opposed to 16 months in patients with unmethylated 
tumors (29). The PCR-based assay used in that trial is being prepared for 
commercial use by MDX Health (Ghent, Belgium).  
 
 
IDH 
 
Somatic mutations of isocitrate dehydrogenase (IDH) genes 1 and 2 have only 
recently been described, but have already had a major impact in diagnostic 
neurooncology (2,6,30,31). The IDH1 gene encodes cytosolic NADP+-dependent 
IDH whereas IDH2 gene encodes mitochondrial NADP+-dependent IDH. IDH 
mutations cluster at codon 132 of the IDH1 respectively codon 172 of the IDH2 gene, 
suggesting that these mutations afford a gain of function to tumor cells. If merely loss 
of IDH function was the main mechanism, any type of mutation resulting in loss of 
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functional enzyme would be tumorigenic. Present concepts include that the mutant 
IDH variants exhibit an altered substrate specificity which results in the production of 
a putative oncometabolite, D-2-hydroxyglutarate. While this oncometabolite has been 
considered a possible biomarker to monitor disease activity in acute myeloid 
leukemia, the only other cancer with a relatively high rate of IDH mutations, D-2-
hydroxyglutarate levels may be too low in the serum of glioma patients to be of 
diagnostic value (32). 
The IDH mutation rate in astrocytic and oligodendroglial gliomas of grades II and III is 
in the range of 60-80% whereas the rate does not exceed 10% in glioblastomas, 
indicating a differential cellular origin of these tumors. Other brain tumors such as 
ependymomas lack IDH mutations. This differential distribution, and the development 
of an antibody recognizing mutant IDH1 R132H protein (33), which accounts for over 
90% of all mutants in gliomas, explains why IDH assessment was rapidly introduced 
into the diagnostic repertoire of neuropathology in many centers. 
Within glioma entities II-IV, patients with IDH-mutant tumors show a longer survival 
than patients with IDH-wild-type tumors (20,34,35). Yet, the IDH status, like the 
1p/19q status, does not predict benefit from a specific type of treatment, e.g., 
radiotherapy versus chemotherapy (20,36,37). Interestingly, the survival of 
glioblastoma patients with IDH mutation is superior to that of anaplastic astrocytoma 
without IDH mutation (38), illustrating that molecular features can profoundly improve 
the prognostic power of the current, largely morphological neuropathological 
assessment. 
 
 
B-Raf 
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B-Raf is a member of the Raf kinase family which belongs to the serin threonine 
kinases and regulates cell growth and division via mitogen-activated protein kinase 
(MAPK) and extracellular signal-related kinases (ERK). Duplications of B-Raf are 
frequent in pilocytic astrocytomas (39,40). Since BRAF mutations are rare in diffuse 
astrocytic gliomas of WHO grades II-IV, their absence or presence may aid in the 
differential diagnosis of pilocytic and higher grade astrocytomas. An activating point 
mutation, B-RafV600E, is found in approximately 60-70% of pleomorphic 
xanthoastrocytomas and 20% of gangliogliomas, but again very rare in other types of 
glioma (41,42). The detection of B-Raf pathway activation might assume therapeutic 
relevance since specific inhibitors of B-Raf such as PLX-4032 are already explored 
for efficacy in malignant melanoma. Moreover, less selective multikinase inhibitors 
such as sorafenib inhibit B-Raf, too. Finally, inhibitors of heat shock protein (HSP) 90, 
which destabilize mutant B-Raf, may be of interest in this regard. 
 
 
Is molecular neuropathology ready for clinical use? 
 
Major progress has been made in recent years to supplement the morphological 
framework of the WHO classification (1) with molecular markers of diagnostic and 
prognostic significance (Table, Figure). MGMT promoter methylation stands out as a 
marker where choice of assay and technical standardization have turned out to be 
most challenging (4). EGFR amplification, 1p/19q codeletion, IDH mutation and B-
Raf alterations are characteristic of specific tumors whereas MGMT promoter 
methylation is not. 1p/19q codeletion, IDH mutation and MGMT promoter methylation 
are strongly prognostic in anaplastic gliomas. Importantly, these three favourable 
markers may not be independent, e.g., the 1p/19q codeletion lost significance upon 
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the multivariate analysis of the NOA-04 trial when MGMT and IDH status were 
included in the analysis (20). Only IDH mutations are confirmed to be prognostic in 
grade II gliomas. In glioblastoma, IDH mutations indicate the origin from a prior lower 
grade lesion, and MGMT promoter methylation is probably both prognostic, and 
predictive for benefit from alkylating agent chemotherapy. Accordingly, molecular 
neuropathology provides a lot of diagnostic and prognostic information, but is still 
largely dispensable for individual clinical decision making. 
 
 
Molecular markers and clinical trial design 
 
Molecular markers have been introduced into the design of clinical trials to enrich 
patient populations, that is, too define more homogeneous patient populations which 
are more likely to respond to treatment in a uniform manner. This strategy has been 
employed for MGMT promoter methylation in the CENTRIC trial for newly diagnosed 
glioblastoma, based on the analysis of a small phase II trial (43) and, based on 
robust historical data (18,19), for the 1p/19q codeletion in the multinational CATNON 
and CODEL trials which are also open in many European countries. As one of the 
next steps, it seems reasonable to exclude glioblastoma patients with IDH mutations 
from future glioblastoma trials. The most convincing use of molecular marker analysis 
would be the analysis of the EGFRvIII mutation in glioblastoma as the requirement 
for inclusion into a vaccination trial targeting specifically this common type of 
mutation (15). 
 
 
Outlook 
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Further areas of biomarker research that are far less advanced in terms of 
implementation in the clinic include the diagnostic and prognostic use of glioma stem 
cell markers as well as the identification of predictive markers for benefit from specific 
types of antiangiogenic treatment. These could include not only tumor tissue 
markers, but also plasma biomarkers such as vascular endothelial growth factor 
(VEGF) family members or their soluble receptors (44,45) or vessel structures 
amenable to advanced imaging techniques such as integrins expressed on the 
luminal vessel wall (46). 
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Table. Molecular markers in glioma: an overview 
 
   Clinical relevance 
 Biological 
significance 
Method of assessment Grade II gliomas Grade III anaplastic gliomas Grade IV glioblastoma 
      
P53 Cell cycle checkpoint, 
DNA repair 
PCR and sequencing and 
immunohistochemistry 
None None None 
      
EGFR Proliferation, invasion PCR or 
immunohistochemistry 
None Suggests possible undergrading 
 consider reclassification as 
glioblastoma 
Often overexpressed (40%), 
EGFRvIII mutation (25%) as a 
possible target for immunotherapy 
      
1p/19q Biological role 
unclear, codeletion of 
chromosomal arms 
1p and 19q linked to 
oligodendroglial 
morphology 
PCR, FISH Controversial, 
probably 
prognostically 
favorable 
Prognostically favourable in 
patients treated with radiotherapy 
or chemotherapy or both 
Rare, significance unclear 
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MGMT DNA repair Methylation-specific PCR Controversial Prognostically favourable in 
patients treated with radiotherapy 
or chemotherapy or both 
Predictive for benefit from 
alkylating agent chemotherapy 
      
IDH Biological role 
unclear, possible link 
to energy metabolism 
and proangiogenic 
pathways 
PCR or 
immunohistochemistry 
(IDHR132H) 
Prognostically 
favourable 
Prognostically favourable in 
patients treated with radiotherapy 
or chemotherapy or both  
Rare, prognostically favourable, 
suggestive of secondary 
glioblastoma 
      
B-Raf Cell growth and 
division 
PCR Possibly 
identifying patients 
responsive to B-
Raf kinase 
inhibitors (?) 
Rare, no significance Rare, no significance 
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Figure legend 
 
Figure. Molecular markers in glioma. A, 1p/19q codeletion. Microsatellite-PCR-based 
analysis of allelic losses of 1p and 19q in an astrocytoma (WHO grade II) (A II) and 
an anaplastic oligodendroglioma (WHO grade III) (AO III). Losses of both markers 
are indicated by arrowheads in AO III, but not A II. B, MGMT promoter methylation. 
Methylation-specific PCR for unmethylated (U) and methylated (M) promoter 
sequences in 5 glioblastoma samples, including the glioblastoma cell line A172 as a 
positive control for methylated and peripheral blood cells as a control for 
unmethylated promoter sequences, as well as water as a negative control (empty). 
C, IDH mutation. Grade II oligoastrocytoma, upper panels: HE staining, lower panels: 
IDH immunostaining, left panels: tumor center, right panels: infiltration zone 
(Courtesy: Jörg Felsberg, Düsseldorf, Germany) (reproduced with permission from 
ref. 7). 
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